Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Salt Lake City, Utah 84108


The purpose of the study is to determine if the combination of AVJ ablation followed by BiV pacing significantly improves functional status and exercise capacity compared to pharmacologic rate control in patients with chronic AF and depressed ejection fraction, regardless of rate or QRS duration.

Study summary:

- This is a prospective, randomized, double blinded, multicenter study - Patients meeting all the enrollment criteria are screened at enrollment and randomized to Group 1 (Pharmacological therapy + Single Chamber ICD) or Group 2 (AVJ Ablation + CRT-D) - Screened patients are implanted with a FDA approved SJM ICD/CRT-D with compatible lead system - Patients are followed at 1, 3, 6 and 12 months post implant - Total # of centers - 20 centers - Sample size - 180 patients


Inclusion Criteria: - Symptomatic permanent AF - Class I or II indication for ICD - LVEF ≤ 35% within 6 months - NYHA class II or III with a history of CHF - Maximal tolerated drug therapy for CHF and rate control with a stable regimen for ≥ 30 days - Ability to independently comprehend and complete a QoL questionnaire - Ability to give informed consent for study participation and willingness and ability to comply with prescribed follow-up tests and scheduled evaluations Exclusion Criteria: - Paroxysmal or persistent AF - Class I indication for pacing (including AVJ ablation for poor rate control) - Ability to walk ≥ 450 meters in 6 minutes - Musculoskeletal disorders that prohibit the completion of a 450 meters walk - NYHA class I or IV at the time of enrollment - A contraindication to taking Coumadin therapy - History of myocardial infarction, percutanous coronary intervention, or CABG in the past 30 days - History of mitral valve surgery - Prior attempts for cardiac resynchronization therapy - The presence of an existing coronary sinus lead or epicardial lead - Life expectancy < 1year - Age < 18 yrs - Current participation in other clinical studies except registry trials - Use of calcium channel blockers - Pregnancy - Inability to give informed consent



Primary Contact:

Principal Investigator
Mohamed Hamdan, MD
University of Utah Health Sciences

Backup Contact:


Location Contact:

Salt Lake City, Utah 84108
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.